Robert Barrow insider trades

Open-market stock purchases and sales by Robert Barrow, Chief Executive Officer at Definium Therapeutics, Inc, from SEC Form 4 filings since Jan 15, 2022.

Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +142%.

Recent trades

DateStockTradeValue
Sep 25, 2026DFTX Definium Therapeutics, IncSold$1.2M
Sep 14, 2026DFTX Definium Therapeutics, IncBought (not open market)—
Sep 3, 2026DFTX Definium Therapeutics, IncSold$722K
Sep 2, 2026DFTX Definium Therapeutics, IncBought (not open market)—
Aug 12, 2026DFTX Definium Therapeutics, IncBought (not open market)—
Jun 25, 2026DFTX Definium Therapeutics, IncSold$1.3M
Jun 22, 2026DFTX Definium Therapeutics, IncBought (not open market)—
Mar 25, 2026DFTX Definium Therapeutics, IncSold$451K
Feb 3, 2026DFTX Definium Therapeutics, IncBought (not open market)—
Dec 26, 2025MNMD Mind Medicine (MindMed) IncSold$339K

Companies traded

  • DFTX Definium Therapeutics, Inc: 4 sales, last Sep 25, 2026
  • MNMD Mind Medicine (MindMed) Inc: 2 buys, 27 sales, last Dec 26, 2025

Get free alerts when Robert Barrow files a new trade →